Oxygen Biotherapeutics (Nasdaq: OXBT) has struck a new supply agreement and distribution agreement with a Swiss firm that will make the company’s cosmetic skin product Dermacyte.
The agreement gives Lausanne, Switzerland-based Valor the exclusive right to sell, import, export, distribute, package label and otherwise commercialize Dermacyte. Before reaching the agreement, Oxygen had handled Dermacyte manufacturing and distribution. Dermacyte is a skin care product that uses Oxygen’s technology to enhance the delivery of oxygen to damaged tissues.
Valor must pay Morrisville-based Oxygen a non-refundable license fee as well as a royalty on Dermacyte sales. Oxygen said that the agreement leaves the company free to focus on its drug development work. Oxygen’s lead program is the experierimental therapy Oxycyte, which is in clinical trials as a potential traumatic brain injury treatment.
